DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Summary
This is the initial Office action on the 18/760260 application filed on 12/10/24.
Claims 1, 21, 55-56 are pending and have been fully considered.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 12/10/24 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 21 is/are rejected under 35 U.S.C. 102a1 as being anticipated by MAGUIRE (WO2016/065341) as supplied by applicant on the IDS dated 12/10/24.
With respect to claim 21, MAGUIRE discloses a delivery apparatus for cells comprising an atomizer (housing) with a support that holds a plate of sample wells (0184) (configured to receive a plate comprising a well); an atomizer emitter which can be a nebulizer (0062) (delivery solution applicator) configured to deliver solution to a well (0175-178, 0182, Fig 2), and pipettes (needle emitters) for adding and removing (capable of providing positive or negative pressure, differential pressure applicator) PBS, solution A, solution b and culture medium (stop solution applicator, culture medium applicator) (0208, Fig 2); and gas propelling the aqueous solution to form a spray to contact the cells (0011, 0030).
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1, 55-56 is/are rejected under 35 U.S.C. 103 as being unpatentable over MAGUIRE (WO2016/065341) in view of CONROY (US2005/0014259) as supplied by applicant on the IDS dated 12/10/24.
Regarding claim 1, MAGUIRE discloses an in vitro method comprising:
providing a delivery apparatus comprising a plate of sample wells (0184) with a population of cells in the well plate that can be non-adherent (providing a population of non-adherent cells) (0013, 0127);
delivering a solution to a well (contacting the cells with a volume of solution) (0175-178); the delivery solution including an aqueous solution including a payload and an alcohol content greater than 5% concentration (0007-0008, 0011), and that the solution contains various ranges of salts, sugars and buffering agents but does not explicitly disclose the aqueous solution is isotonic.
However, CONROY discloses a method of delivering a nucleic acid (payload) to a cell wherein the nucleic acid is carried in a solution comprising an osmolarity essentially isotonic with the osmolarity of the physiological milieu of the cell to be treated (0019, 0031).
At the time the invention was filed it would have been obvious to one of ordinary skill in the art to modify the delivery solution of MAGUIRE to include the aqueous solution containing the appropriate amount of solutes to be isotonic as taught by CONROY because the solution shows enhanced ability to deliver nucleic acid to cells resulting in a high-level expression of transfected genes (0017) while approximating physiological conditions (0095).
Regarding claim 55, MAGUIRE discloses a delivery solution (composition) including an aqueous solution including a payload (cargo compound or composition) and an ethanol content greater than 5% concentration (0007-0008, 0011, 0153, 0157) and contains KCL at 12-24 mM or 46mM (KCl concentration is between 10-500 mM) (0148, 0151), 0254 and that the solution contains various ranges of salts, sugars and buffering agents but does not explicitly disclose the aqueous solution is isotonic.
However, CONROY discloses a method of delivering a nucleic acid (payload) to a cell wherein the nucleic acid is carried in a solution comprising an osmolarity essentially isotonic with the osmolarity of the physiological milieu of the cell to be treated (0019, 0031).
At the time the invention was filed it would have been obvious to one of ordinary skill in the art to modify the delivery solution of MAGUIRE to include the aqueous solution containing the appropriate amount of solutes to be isotonic as taught by CONROY because the solution shows enhanced ability to deliver nucleic acid to cells resulting in a high-level expression of transfected genes (0017) while approximating physiological conditions (0095).
Regarding claim 56, MAGUIRE discloses the ethanol concentration can vary between 2-45% ethanol and preferably 20-30% (0151) ethanol (encompasses claimed 27%) and contains 46mM of a salt such as KCl or in other examples varying concentrations of salts up to 2.8X (0151, 0254-55). At the time the invention was filed it would have been obvious tone having ordinary skill in the art to choose the claimed ranges of components in the composition, because when the claimed ranges overlap or lie inside ranges disclosed by the prior art a prima facie case of obviousness exists. Additionally, it has been held that where the general conditions of a claim are disclosed in the prior art discovering the optimum or workable ranges involves only routing skill in the art. MPEP 2144.05.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 21 and 55 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 23 respectively of U.S. Patent No. 11981915. Although the claims at issue are not identical, they are not patentably distinct from each other because the examined claims in this instant application are either anticipated by, or would have been obvious over the reference claims. The patented claims are directed to the same subject matter and the difference lies in the fact the patent claims include many more elements and thus is much more specific and fall entirely within the scope of the claims in the instant application, therefore the instant claims are anticipated by the claims of the patent.
Claims 1, 21, 55 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 28, 1, 15 respectively of U.S. Patent No. 12060570. Although the claims at issue are not identical, they are not patentably distinct from each other because the examined claims in this instant application are either anticipated by, or would have been obvious over the reference claims. The patented claims are directed to the same subject matter and the difference lies in the fact the patent claims include many more elements and thus is much more specific and fall entirely within the scope of the claims in the instant application, therefore the instant claims are anticipated by the claims of the patent.
Claims 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 8 of U.S. Patent No. 12104166. Although the claims at issue are not identical, they are not patentably distinct from each other because the examined claims in this instant application are either anticipated by, or would have been obvious over the reference claims. The patented claims are directed to the same subject matter and the difference lies in the fact the patent claims include many more elements and thus is much more specific and fall entirely within the scope of the claims in the instant application, therefore the instant claims are anticipated by the claims of the patent.
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See additional reference cited on the attached PTO 892 that present the state of the art.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIELLE B HENKEL whose telephone number is (571)270-5505. The examiner can normally be reached M-Th 11-7 EST, Alt. Fridays.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Marcheschi can be reached at 571-272-1374. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/DANIELLE B HENKEL/Examiner, Art Unit 1799
/William H. Beisner/Primary Examiner, Art Unit 1799